NorthWest Biotherapeutics Inc (NWBO)

[antihama]

So true, yet the beanie will not become obsolete. After therapy w murcidencel, they, w/o any alternatives at this time, and they can afford it, might try the beanie. Even. in the future, after combo therapies w murcidencel are developed that may greatly improve efficacy but not cure GBM, they might want to try the beanie. It was interesting reading the JA regarding the beanie and DCVax-L

Eight of the 232 patients (3.4%) receiving DCVax-L were treated with tumor-treating fields (TTF) following recurrence. Four of those 8 patients (50.0%) continued receiving DCVax-L while using the TTF device after recurrence and survived from 22.6 to more than 72.7 months from randomization. Four of the 8 patients (50.0%) stopped receiving DCVax-L while using the TTF device post-recurrence, and survived from 8.9 to 29.2 months from randomization.